Univariate analysis of demographics and clinical characteristics by molecular group
| Variables | KIAA1549:BRAF Fusion | BRAF V600E | Wild-Type/Other | P1 | P2 |
|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | (Fusion vs V600E vs WT) | (Fusion vs V600E) | |
| Sex | .3583 | .4436 | |||
| Male | 16 (53) | 8 (42) | 7 (33) | ||
| Female | 14 (47) | 11 (58) | 14 (67) | ||
| Age at time of MR imaging (yr) | .0012 | .0126 | |||
| Median | 3.3 (1.56–5.10)a | 9.7 (5.08–14.25)a | 10.5 (6.42–14.58)a | ||
| Progression of disease | .5769 | .3669 | |||
| Yes | 15 (50) | 12 (63) | 13 (62) | ||
| No | 15 (50) | 7 (37) | 8 (38) | ||
| WHO grade | .0902 | .0724 | |||
| Grade I | 27 (90) | 13 (68) | 18 (95) | ||
| Grade II | 3 (10) | 6 (32) | 1 (5) | ||
| Tumor location | <.0001 | <.0001 | |||
| Brainstem | 2 (7) | 1 (5) | 1 (5) | ||
| Cerebral hemisphere | 3 (10) | 13 (68) | 13 (62) | ||
| OPHG | 7 (23) | 4 (21) | 3 (14) | ||
| Posterior fossa | 17 (57) | 0 (0) | 4 (19) | ||
| Spinal cord | 1 (3) | 1 (5) | 0 (0) | ||
| Metastatic status | .8107 | 1.0000 | |||
| Yes | 1 (3) | 1 (5) | 2 (10) | ||
| No | 29 (97) | 18 (95) | 19 (90) |
Note:—WT indicates wild-type; OPHG, optic pathway/hypothalamic glioma.
↵a Median and 95% confidence interval.